Artidis has announced the commencement of its worldwide multicentre clinical trial, ARTIDIS Nanomechanical Generated Measurements for Early Lesions (ANGEL), for breast cancer care.
The trial is led by Olga Keith Wiess surgery chair and Baylor College of Medicine Breast Cancer Surgery section chief Dr Alastair Thompson and seeks to transform breast cancer care by leveraging tissue nanomechanics for improved diagnostics and treatment optimisation.
It intends to validate the clinical utility of the Nanomechanical Signature by assessing the ARTIDIS bedside device’s capacity to assess biopsies and precisely detect breast cancer subtypes.
Related: Samay reports positive results for AI-assisted wearable device for COPD
The device integrates into standard-of-care workflows and offers a quick solution to detect malignant tissue and preserve tissue integrity for subsequent evaluations.
Besides, the advanced ARTIDISNET incorporates clinical achievement data with the Nanomechanical Signature to deliver an integrated approach to personalised patient diagnostics and treatment.
The study will also focus on predicting treatment response and clinical outcomes, particularly in the context of neoadjuvant therapy (NAT).
